Search

Your search keyword '"Taube, Eliane"' showing total 175 results
Start Over Author "Taube, Eliane"
175 results on '"Taube, Eliane"'

1. AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication

Author

Monjé, Nanna, Dragomir, Mihnea P., Sinn, Bruno V., Hoffmann, Inga, Makhmut, Anuar, Simon, Tincy, Kunze, Catarina A., Ihlow, Jana, Schmitt, Wolfgang D., Pohl, Jonathan, Piwonski, Iris, Marchenko, Sofya, Keunecke, Carlotta, Calina, Teodor G., Tiso, Francesca, Kulbe, Hagen, Kreuzinger, Caroline, Cacsire Castillo-Tong, Dan, Sehouli, Jalid, Braicu, Elena I., Denkert, Carsten, Darb-Esfahani, Silvia, Kübler, Kirsten, Capper, David, Coscia, Fabian, Morkel, Markus, Horst, David, Sers, Christine, and Taube, Eliane T.

Published
2024
Full Text
View/download PDF

2. High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma

Author

Jank, Paul, Leichsenring, Jonas, Kolb, Svenja, Hoffmann, Inga, Bischoff, Philip, Kunze, Catarina Alisa, Dragomir, Mihnea P., Gleitsmann, Moritz, Jesinghaus, Moritz, Schmitt, Wolfgang D., Kulbe, Hagen, Sers, Christine, Stenzinger, Albrecht, Sehouli, Jalid, Braicu, Ioana Elena, Westhoff, Christina, Horst, David, Denkert, Carsten, Gröschel, Stefan, and Taube, Eliane T.

Published
2023
Full Text
View/download PDF

4. LRP1B—a prognostic marker in tubo-ovarian high-grade serous carcinoma

Author

Kolb, Svenja, Hoffmann, Inga, Monjé, Nanna, Dragomir, Mihnea P., Jank, Paul, Bischoff, Philip, Keunecke, Carlotta, Pohl, Jonathan, Kunze, Catarina Alisa, Marchenko, Sofya, Schmitt, Wolfgang D., Kulbe, Hagen, Sers, Christine, Sehouli, Jalid, Braicu, Elena Ioana, Denkert, Carsten, Darb-Esfahani, Silvia, Horst, David, Sinn, Bruno V., and Taube, Eliane T.

Published
2023
Full Text
View/download PDF

5. Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer

Author

Hoffmann, Inga, Dragomir, Mihnea P., Monjé, Nanna, Keunecke, Carlotta, Kunze, Catarina Alisa, Schallenberg, Simon, Marchenko, Sofya, Schmitt, Wolfgang D., Kulbe, Hagen, Sehouli, Jalid, Braicu, Ioana Elena, Jank, Paul, Denkert, Carsten, Darb-Esfahani, Silvia, Horst, David, Sinn, Bruno V., Sers, Christine, Bischoff, Philip, and Taube, Eliane T.

Published
2023
Full Text
View/download PDF

6. Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium

Author

Glajzer, Jacek, Castillo-Tong, Dan Cacsire, Richter, Rolf, Vergote, Ignace, Kulbe, Hagen, Vanderstichele, Adriaan, Ruscito, Ilary, Trillsch, Fabian, Mustea, Alexander, Kreuzinger, Caroline, Gourley, Charlie, Gabra, Hani, Taube, Eliane T., Dorigo, Oliver, Horst, David, Keunecke, Carlotta, Baum, Joanna, Angelotti, Timothy, Sehouli, Jalid, and Braicu, Elena Ioana

Published
2023
Full Text
View/download PDF

8. Gene expression markers in peripheral blood and outcome in patients with platinum‐resistant ovarian cancer: A study of the European GANNET53 consortium.

Author

Obermayr, Eva, Mohr, Thomas, Schuster, Eva, Braicu, Elena Ioana, Taube, Eliane, Sehouli, Jalid, Vergote, Ignace, Pujade‐Lauraine, Eric, Ray‐Coquard, Isabelle, Harter, Philipp, Wimberger, Pauline, Joly‐Lobbedez, Florence, Mahner, Sven, Moll, Ute Martha, Concin, Nicole, and Zeillinger, Robert

Subjects
OVARIAN cancer, GENE expression, POLYMERASE chain reaction, DRUG administration, COMBINATION drug therapy
Abstract

Disease progression is a major problem in ovarian cancer. There are very few treatment options for patients with platinum‐resistant ovarian cancer (PROC), and therefore, these patients have a particularly poor prognosis. The aim of the present study was to identify markers for monitoring the response of 123 PROC patients enrolled in the Phase I/II GANNET53 clinical trial, which evaluated the efficacy of Ganetespib in combination with standard chemotherapy versus standard chemotherapy alone. In total, 474 blood samples were collected, comprising baseline samples taken before the first administration of the study drugs and serial samples taken during treatment until further disease progression (PD). After microfluidic enrichment, 27 gene transcripts were analyzed using quantitative polymerase chain reaction and their utility for disease monitoring was evaluated. At baseline, ERCC1 was associated with an increased risk of PD (hazard ratio [HR] 1.75, 95% confidence interval [CI]: 1.20–2.55; p = 0.005), while baseline CDH1 and ESR1 may have a risk‐reducing effect (CDH1 HR 0.66, 95% CI: 0.46–0.96; p = 0.024; ESR1 HR 0.58, 95% CI: 0.39–0.86; p = 0.002). ERCC1 was observed significantly more often (72.7% vs. 53.9%; p = 0.032) and ESR1 significantly less frequently (59.1% vs. 78.3%; p = 0.018) in blood samples taken at radiologically confirmed PD than at controlled disease. At any time during treatment, ERCC1‐presence and ESR1‐absence were associated with short PFS and with higher odds of PD within 6 months (odds ratio 12.77, 95% CI: 4.08–39.97; p < 0.001). Our study demonstrates the clinical relevance of ESR1 and ERCC1 and may encourage the analysis of liquid biopsy samples for the management of PROC patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy—Innovative Models Prolong Survival (OCTIPS) Consortium

Author

Glajzer, Jacek, Castillo-Tong, Dan Cacsire, Richter, Rolf, Vergote, Ignace, Kulbe, Hagen, Vanderstichele, Adriaan, Ruscito, Ilary, Trillsch, Fabian, Mustea, Alexander, Kreuzinger, Caroline, Gourley, Charlie, Gabra, Hani, Taube, Eliane T., Dorigo, Oliver, Horst, David, Keunecke, Carlotta, Baum, Joanna, Angelotti, Timothy, Sehouli, Jalid, and Braicu, Elena Ioana

Published
2023
Full Text
View/download PDF

11. DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status

Author

Jurmeister, Philipp, Weber, Karsten, Villegas, Sonia, Karn, Thomas, Untch, Michael, Thieme, Anne, Müller, Volkmar, Taube, Eliane, Fasching, Peter, Schmitt, Wolfgang D., Marmé, Frederik, Stickeler, Elmar, Sinn, Bruno V., Jank, Paul, Schem, Christian, Klauschen, Frederick, van Mackelenbergh, Marion, Denkert, Carsten, Loibl, Sibylle, and Capper, David

Published
2021
Full Text
View/download PDF

12. Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium

Author

Guan, Jun, Darb-Esfahani, Silvia, Richter, Rolf, Taube, Eliane T., Ruscito, Ilary, Mahner, Sven, Woelber, Linn, Prieske, Katharina, Concin, Nicole, Vergote, Ignace, Van Nieuwenhuysen, Els, Achimas-Cadariu, Patriciu, Glajzer, Joanna, Woopen, Hannah, Stanske, Mandy, Kulbe, Hagen, Denkert, Carsten, Sehouli, Jalid, and Braicu, Elena Ioana

Published
2019
Full Text
View/download PDF

15. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy

Author

Sinn, Bruno Valentin, Weber, Karsten E., Schmitt, Wolfgang Daniel, Fasching, Peter A., Symmans, William Fraser, Blohmer, Jens-Uwe, Karn, Thomas, Taube, Eliane Tabea, Klauschen, Frederick, Marmé, Frederik, Schem, Christian, Stickeler, Elmar, Ataseven, Beyhan, Huober, Jens, von Minckwitz, Gunter, Seliger, Barbara, Denkert, Carsten, and Loibl, Sibylle

Published
2019
Full Text
View/download PDF

17. Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).

Author

Ruscito, Ilary, Cacsire Castillo-Tong, Dan, Vergote, Ignace, Ignat, Iulia, Stanske, Mandy, Vanderstichele, Adriaan, Glajzer, Jacek, Kulbe, Hagen, Trillsch, Fabian, Mustea, Alexander, Kreuzinger, Caroline, Benedetti Panici, Pierluigi, Gourley, Charlie, Gabra, Hani, Nuti, Marianna, Taube, Eliane T., Kessler, Mirjana, Sehouli, Jalid, Darb-Esfahani, Silvia, and Braicu, Elena Ioana

Published
2018
Full Text
View/download PDF

19. ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy—Innovative Models Prolong Survival (OCTIPS) Consortium

Author

Glajzer, Jacek, primary, Castillo-Tong, Dan Cacsire, additional, Richter, Rolf, additional, Vergote, Ignace, additional, Kulbe, Hagen, additional, Vanderstichele, Adriaan, additional, Ruscito, Ilary, additional, Trillsch, Fabian, additional, Mustea, Alexander, additional, Kreuzinger, Caroline, additional, Gourley, Charlie, additional, Gabra, Hani, additional, Taube, Eliane T., additional, Dorigo, Oliver, additional, Horst, David, additional, Keunecke, Carlotta, additional, Baum, Joanna, additional, Angelotti, Timothy, additional, Sehouli, Jalid, additional, and Braicu, Elena Ioana, additional

Published
2022
Full Text
View/download PDF

20. Low Expression of RGS2 Promotes Poor Prognosis in High-Grade Serous Ovarian Cancer

Author

Ihlow, Jana, primary, Monjé, Nanna, additional, Hoffmann, Inga, additional, Bischoff, Philip, additional, Sinn, Bruno Valentin, additional, Schmitt, Wolfgang Daniel, additional, Kunze, Catarina Alisa, additional, Darb-Esfahani, Sylvia, additional, Kulbe, Hagen, additional, Braicu, Elena Ioana, additional, Sehouli, Jalid, additional, Denkert, Carsten, additional, Horst, David, additional, and Taube, Eliane Tabea, additional

Published
2022
Full Text
View/download PDF

21. Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium

Author

Glajzer, Jacek, primary, Castillo-Tong, Dan Cacsire, additional, Richter, Rolf, additional, Vergote, Ignace, additional, Kulbe, Hagen, additional, Vanderstichele, Adriaan, additional, Ruscito, Ilary, additional, Trillsch, Fabian, additional, Mustea, Alexander, additional, Kreuzinger, Caroline, additional, Gourley, Charlie, additional, Gabra, Hani, additional, Taube, Eliane T., additional, Dorigo, Oliver, additional, Horst, David, additional, Keunecke, Carlotta, additional, Baum, Joanna, additional, Angelotti, Timothy, additional, Sehouli, Jalid, additional, and Braicu, Elena Ioana, additional

Published
2022
Full Text
View/download PDF

22. Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer

Author

Keunecke, Carlotta, primary, Kulbe, Hagen, additional, Dreher, Felix, additional, Taube, Eliane T., additional, Chekerov, Radoslav, additional, Horst, David, additional, Hummel, Michael, additional, Kessler, Thomas, additional, Pietzner, Klaus, additional, Kassuhn, Wanja, additional, Heitz, Florian, additional, Muallem, Mustafa Z., additional, Lang, Susan M., additional, Vergote, Ignace, additional, Dorigo, Oliver, additional, Lammert, Hedwig, additional, du Bois, Andreas, additional, Angelotti, Tim, additional, Fotopoulou, Christina, additional, Sehouli, Jalid, additional, and Braicu, Elena I., additional

Published
2022
Full Text
View/download PDF

23. Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma

Author

Marchenko, Sofya, primary, Piwonski, Iris, additional, Hoffmann, Inga, additional, Sinn, Bruno Valentin, additional, Kunze, Catarina Alisa, additional, Monjé, Nanna, additional, Pohl, Jonathan, additional, Kulbe, Hagen, additional, Schmitt, Wolfgang Daniel, additional, Darb-Esfahani, Sylvia, additional, Braicu, Elena Ioana, additional, von Brünneck, Ann-Christin, additional, Sehouli, Jalid, additional, Denkert, Carsten, additional, Horst, David, additional, Jöhrens, Korinna, additional, and Taube, Eliane Tabea, additional

Published
2022
Full Text
View/download PDF

25. Neurogenic Inflammation in the Context of Endometriosis—What Do We Know?

Author

Velho, Renata Voltolini, Taube, Eliane, Sehouli, Jalid, and Mechsner, Sylvia

Subjects
endometriosis, Sensory Receptor Cells, neurogenic inflammation, QH301-705.5, Review, Pelvic Pain, Chemistry, Gene Expression Regulation, inflammation, peripheral nerve, nerve signalling, Humans, neuroimmune modulation, Female, Nerve Growth Factors, Biology (General), non-hormonal treatment, QD1-999, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
Abstract

Endometriosis (EM) is an estrogen-dependent disease characterized by the presence of epithelial, stromal, and smooth muscle cells outside the uterine cavity. It is a chronic and debilitating condition affecting ~10% of women. EM is characterized by infertility and pain, such as dysmenorrhea, chronic pelvic pain, dyspareunia, dysuria, and dyschezia. Although EM was first described in 1860, its aetiology and pathogenesis remain uncertain. Recent evidence demonstrates that the peripheral nervous system plays an important role in the pathophysiology of this disease. Sensory nerves, which surround and innervate endometriotic lesions, not only drive the chronic and debilitating pain associated with EM but also contribute to a growth phenotype by secreting neurotrophic factors and interacting with surrounding immune cells. Here we review the role that peripheral nerves play in driving and maintaining endometriotic lesions. A better understanding of the role of this system, as well as its interactions with immune cells, will unearth novel disease-relevant pathways and targets, providing new therapeutics and better-tailored treatment options.

Published
2021

28. Correction: MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial

Author

Jank, Paul, primary, Gehlhaar, Claire, additional, Lederer, Bianca, additional, Fontanella, Caterina, additional, Schneeweiss, Andreas, additional, Karn, Thomas, additional, Marmé, Frederik, additional, Sinn, Hans-Peter, additional, van Mackelenbergh, Marion, additional, Sinn, Bruno, additional, Zahm, Dirk-Michael, additional, Ingold-Heppner, Barbara, additional, Schem, Christian, additional, Stickeler, Elmar, additional, Fasching, Peter A., additional, Nekljudova, Valentina, additional, Taube, Eliane Tabea, additional, Heppner, Frank, additional, Müller, Volkmar, additional, Denkert, Carsten, additional, and Loibl, Sibylle, additional

Published
2021
Full Text
View/download PDF

29. Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network

Author

Sehouli, Jalid, Braicu, Elena Ioana, Richter, Rolf, Denkert, Carsten, Jank, Paul, Jurmeister, Philipp Sebastian, Kunze, Catarina Alisa, Budczies, Jan, Darb-Esfahani, Sylvia, Schmitt, Wolfgang Daniel, Traut, Alexander, Grabowski, Jacek, Taube, Eliane Tabea, Plett, Helmut, and Taube, ElianeTabea

Subjects
Adult, 0301 basic medicine, Oncology, medicine.medical_specialty, Medizin, Estrogen receptor, Pathology and Forensic Medicine, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Ovarian carcinoma, Internal medicine, Progesterone receptor, Biomarkers, Tumor, medicine, Humans, Aged, Retrospective Studies, Aged, 80 and over, Ovarian Neoplasms, biology, business.industry, Middle Aged, Prognosis, medicine.disease, Immunohistochemistry, Progression-Free Survival, Cystadenocarcinoma, Serous, Survival Rate, Serous fluid, Ki-67 Antigen, 030104 developmental biology, Receptors, Estrogen, Hormone receptor, 030220 oncology & carcinogenesis, Ki-67, biology.protein, Female, Cancer biomarkers, Receptors, Progesterone, business, Ovarian cancer
Abstract

Summary Low-grade serous ovarian carcinoma (LGSOC) has recently come up as a distinct rare entity of epithelial ovarian cancer. Predictive and prognostic markers are not well studied yet. Because Ki-67 and hormone receptors (HR) have been established as relevant cancer biomarkers in several malignant tumors, we evaluated Ki-67 and HR expression rates by immunohistochemistry in 68 patients with LGSOC. We used a standardized cutoff finder algorithm to analyze prognostic significance for overall survival (OS) and progression-free survival (PFS). Cox regression showed a significant continuous decrease in OS for higher proliferation rates with an HR of 1.07% (95% confidence interval, 1.01%-3.67%; P = .048) but not in PFS (P = .86). Cutoff finder analysis revealed the best possible cutoff for OS at 6.28% (P = .04) and for PFS at 1.85% proliferative activity (P = .04). Estrogen receptors (ERs) were expressed in most LGSOC patients (n = 61; 89.7%), progesterone receptor (PR) in about half of patients (n = 33; 48.5%). For both ER/PR, a statistically significant cutoff for PFS could be determined, which was at 75% of positive tumor cells for ER (P = .02) and at 15% of positive tumor cells for PR (P = .03). For OS, HR expression showed a tendency toward better OS for HR-positive tumors but did not turn out statistically significant. Our results show that Ki-67 is a valuable prognostic marker in the subgroup of LGSOC. We could also show that most LGSOCs express HRs but that this expression is associated with a better PFS, a finding valuable in times of antihormonal therapy in LGSOC.

Published
2019

30. Additional file 1 of DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status

Author

Jurmeister, Philipp, Weber, Karsten, Villegas, Sonia, Karn, Thomas, Untch, Michael, Thieme, Anne, Müller, Volkmar, Taube, Eliane, Fasching, Peter, Schmitt, Wolfgang D., Marmé, Frederik, Stickeler, Elmar, Sinn, Bruno V., Jank, Paul, Schem, Christian, Klauschen, Frederick, van Mackelenbergh, Marion, Denkert, Carsten, Loibl, Sibylle, and Capper, David

Abstract

Additional file 1. Fig. S1: t-distributed stochastic neighbor embedding (t-SNE) plots showing the estimated tumor purity of The Cancer Genome Atlas samples based on manual estimation using light microscopy (a), RNAseq data (ESTIMATE; b), copy number variations (ABSOLUTE; c), DNA methylation (LUMP; d) and a combined score (CPE; e).

Published
2021
Full Text
View/download PDF

31. Additional file 2 of DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status

Author

Jurmeister, Philipp, Weber, Karsten, Villegas, Sonia, Karn, Thomas, Untch, Michael, Thieme, Anne, Müller, Volkmar, Taube, Eliane, Fasching, Peter, Schmitt, Wolfgang D., Marmé, Frederik, Stickeler, Elmar, Sinn, Bruno V., Jank, Paul, Schem, Christian, Klauschen, Frederick, van Mackelenbergh, Marion, Denkert, Carsten, Loibl, Sibylle, and Capper, David

Subjects
skin and connective tissue diseases
Abstract

Additional file 2. Fig. S2: Flowchart showing the composition of the study cohort with samples from the publicly available “The Cancer Genome Atlas” (TCGA) dataset as well as specimens from the clinical GeparSixto and GeparSepto trial. Abbreviations: BRCA = breast cancer; ER = estrogen receptor; PR = progesterone receptor; TNBC = triple negative breast cancer; t-SNE = t-distributed stochastic neighbor embedding.

Published
2021
Full Text
View/download PDF

32. Classification of molecular subtypes of high-grade serous ovarian cancer by MALDI-Imaging.

Author

Kassuhn, Wanja Nikolai, primary, Klein, Oliver, additional, Darb-Esfahani, Silvia, additional, Lammert, Hedwig, additional, Handzik, Sylwia, additional, Taube, Eliane T, additional, Schmitt, Wolfgang D, additional, Dorigo, Oliver, additional, Horst, David, additional, Keunecke, Carlotta, additional, Dreher, Felix, additional, George, Joshy, additional, Bowtell, David, additional, Hummel, Michael, additional, Sehouli, Jalid, additional, Blüthgen, Nils, additional, Kulbe, Hagen, additional, and Braicu, Elena Ioana, additional

Published
2021
Full Text
View/download PDF

33. Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging

Author

Kassuhn, Wanja, primary, Klein, Oliver, additional, Darb-Esfahani, Silvia, additional, Lammert, Hedwig, additional, Handzik, Sylwia, additional, Taube, Eliane T., additional, Schmitt, Wolfgang D., additional, Keunecke, Carlotta, additional, Horst, David, additional, Dreher, Felix, additional, George, Joshy, additional, Bowtell, David D., additional, Dorigo, Oliver, additional, Hummel, Michael, additional, Sehouli, Jalid, additional, Blüthgen, Nils, additional, Kulbe, Hagen, additional, and Braicu, Elena I., additional

Published
2021
Full Text
View/download PDF

37. Management of malignant dysgerminoma of the ovary.

Author

Arndt, Tjadina, Tabea Taube, Eliane, Deubzer, Hedwig E., Rothe, Karin, Calaminus, Gabriele, Sehouli, Jalid, and Pietzner, Klaus

Subjects
*DISGERMINOMA, *OVARIAN tumors, *CANCER chemotherapy, *LITERATURE reviews, *SURGICAL excision
Abstract

The evolution of treatment for malignant ovarian germ cell tumors has been one of the most successful in the history of gynecologic oncology, with dysgerminoma as the most common type of malignant ovarian germ cell tumors. Since the introduction of platinumbased chemotherapy in the 1980s, 5-year survival rates for early-stage dysgerminomas have been close to 100%, and as high as 98% for advanced stages. Despite this remarkable achievement, many questions remain in routine treatment. By performing a literature review, we aim to highlight both the current treatment of malignant dysgerminoma and unanswered questions in the modern management of this disease. These issues relate firstly to surgical therapy, such as the role of routine omentectomy and lymphadenectomy, the value of complete surgical resection, and the possibility of fertility-sparing surgery. Second, chemotherapy and the question of the possibility of de-escalation in early stages and the potential of neoadjuvant chemotherapy in advanced stages will be addressed. Finally, a brief overview of the current developments of new drug treatment regimens will be given. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

40. MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial

Author

Jank, Paul, primary, Gehlhaar, Claire, additional, Bianca, Lederer, additional, Caterina, Fontanella, additional, Andreas, Schneeweiss, additional, Karn, Thomas, additional, Marmé, Frederik, additional, Sinn, Hans-Peter, additional, van Mackelenbergh, Marion, additional, Sinn, Bruno, additional, Zahm, Dirk-Michael, additional, Ingold-Heppner, Barbara, additional, Schem, Christian, additional, Stickeler, Elmar, additional, Fasching, Peter A., additional, Nekljudova, Valentina, additional, Taube, Eliane Tabea, additional, Heppner, Frank, additional, Müller, Volkmar, additional, Denkert, Carsten, additional, and Loibl, Sibylle, additional

Published
2020
Full Text
View/download PDF

41. Discovery of Prognostic Markers for Early-Stage High-Grade Serous Ovarian Cancer by Maldi-Imaging

Author

Kulbe, Hagen, primary, Klein, Oliver, additional, Wu, Zhiyang, additional, Taube, Eliane T., additional, Kassuhn, Wanja, additional, Horst, David, additional, Darb-Esfahani, Silvia, additional, Jank, Paul, additional, Abobaker, Salem, additional, Ringel, Frauke, additional, du Bois, Andreas, additional, Heitz, Florian, additional, Sehouli, Jalid, additional, and Braicu, Elena I., additional

Published
2020
Full Text
View/download PDF

43. Stable expansion of high‐grade serous ovarian cancer organoids requires a low‐Wnt environment

Author

Hoffmann, Karen, primary, Berger, Hilmar, additional, Kulbe, Hagen, additional, Thillainadarasan, Sukanija, additional, Mollenkopf, Hans‐Joachim, additional, Zemojtel, Tomasz, additional, Taube, Eliane, additional, Darb‐Esfahani, Silvia, additional, Mangler, Mandy, additional, Sehouli, Jalid, additional, Chekerov, Radoslav, additional, Braicu, Elena I, additional, Meyer, Thomas F, additional, and Kessler, Mirjana, additional

Published
2020
Full Text
View/download PDF

44. Rapid progression of aortic and mitral stenosis in a patient with AA amyloidosis: a case report

Author

Frumkin, David, Taube, Eliane Tabea, Stangl, Karl, and Knebel, Fabian

Subjects
Chronic kidney disease, Case report, Left ventricular hypertrophy, Case Reports, Cardiac amyloidosis, Aortic valve stenosis, Mitral valve stenosis, Dialysis, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
Abstract

Background Aortic stenosis is a common finding in cardiac amyloidosis (CA). Younger patients often remain asymptomatic. If unrecognized, this can lead to serious complications such as heart failure. Progression of aortic stenosis can be accelerated in patients with chronic kidney disease and need for dialysis. Perioperative risk in these patients is often high due to the underlying systemic disease. Case summary A 40-year-old Caucasian man with known AA amyloidosis, highly active Ankylosing Spondylitis and need for chronic dialysis due to end-stage chronic renal failure presented for echocardiographic routine exam without reporting any cardiac symptoms. At the last visit 4 years ago, a normal heart valve function was noted and no echocardiographic follow-up was performed in the following. Now, rapid progression with severe aortic valve and mitral valve stenosis was stated and the patient underwent combined aortic and mitral surgical valve replacement following discussion in the multidisciplinary cardiology meeting. Macroscopic examination of the valves revealed significant calcification and histological examination showed the high presence of amyloid by Congo-red staining and immunohistological staining for AA-Amyloid. Both valve prosthetic devices showed normal function as well as a normal left ventricular ejection fraction in initial post-operative transoesophageal echocardiography. After prolonged and complicated post-operative course in the intensive care unit the patient died 3 months after surgery due to intractable multiorgan failure in combined severe abdominal septic and cardiogenic shock. Discussion Concomitant CA and chronic dialysis can accelerate the onset of severe aortic valve stenosis. Young patients, as in this case, often stay asymptomatic, perioperative risk increases with duration of chronic dialysis and severity of valve stenosis. This increases the need for regular short-term echocardiographic examinations even in clinical stable patients.

Published
2019

45. MOESM3 of Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy

Author

Sinn, Bruno, Weber, Karsten, Schmitt, Wolfgang, Fasching, Peter, Symmans, William, Jens-Uwe Blohmer, Karn, Thomas, Taube, Eliane, Klauschen, Frederick, Marmé, Frederik, Schem, Christian, Stickeler, Elmar, Ataseven, Beyhan, Huober, Jens, Minckwitz, Gunter, Seliger, Barbara, Denkert, Carsten, and Loibl, Sibylle

Abstract

Additional file 3: Table S1. Patient and tumor characteristics of the German Breast Group GeparTrio cohort that was evaluated by immunohistochemistry for HLA class I HC expression compared to frequencies in the overall study population. Table S2. Patient and tumor characteristics of the HR+/HER2- subset of the GeparTrio cohort (immunohistochemistry) and the MD Anderson Cancer Center cohort (Affymetrix U133A microarrays). Table S3. Univariate Cox and logistic regression within tumor subtypes and multivariate Cox and logistic regression in patients with HR+/HER2- breast cancer using the percentage of tumor cells positively stained for MHC I. Table S4. Correlations (Spearman’s ρ) of the immune cell metagenes with HLA-A expression, ESR1 and AURKA expression as a surrogate marker for proliferation.

Published
2019
Full Text
View/download PDF

47. Preservation of stemness in high-grade serous ovarian cancer organoids requires low Wnt environment

Author

Hoffmann, Karen, primary, Berger, Hilmar, additional, Kulbe, Hagen, additional, Thillainadarasan, Sukanija, additional, Mollenkopf, Hans-Joachim, additional, Zemojtel, Tomasz, additional, Taube, Eliane, additional, Darb-Esfahani, Silvia, additional, Mangler, Mandy, additional, Sehouli, Jalid, additional, Chekerov, Radoslav, additional, Braicu, Elena, additional, Meyer, Thomas F., additional, and Kessler, Mirjana, additional

Published
2019
Full Text
View/download PDF

50. Dynamic of molecular subtypes of high‐grade serous ovarian cancer in paired primary and relapsed biopsies.

Author

Braicu, Elena Ioana, primary, Kulbe, Hagen, additional, Dreher, Felix, additional, Taube, Eliane T, additional, Ringel, Frauke, additional, Welsch, Gabriele, additional, Darb-Esfahani, Silvia, additional, Keunecke, Carlotta, additional, Kessler, Thomas, additional, Wierling, Christoph, additional, Jank, Paul, additional, Denkert, Carsten, additional, Lammert, Hedwig, additional, Hummel, Michael, additional, and Sehouli, Jalid, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results